Opticyte

We're excited for Lori Arakaki to be a featured speaker at the Optica #MedTech Industry Summit this fall. It's an honor and fantastic opportunity to engage with other stakeholders for optics-based medical devices. Lori will be sharing details of our VitalO₂ monitor for noninvasive blood and cellular oxygenation measurement. Learn more about the conference here: https://lnkd.in/gxU3csuk

An observational study conducted by the University of Washington and Swedish has been using Opticyte’s VitalO₂ monitor to collect data during cardiac surgery and recovery. The study has now completed enrollment with data on 60 patients! 🌟   The study was designed to see if Cell O₂ can help predict and identify vasoplegia, a dangerous form of shock that can occur during or after cardio-pulmonary bypass.  A huge THANK YOU to all the study staff, clinical teams, and patient volunteers for their support of this research.  

We loved spending time at WEB | Health Tech with so many incredible founders like Lori Arakaki, co-founder and CEO at Opticyte. Opticyte is developing a noninvasive medical devise to monitor blood and cell oxygenation, with the advantage of eliminating bias due to skin tone.  

It was an impactful and truly enjoyable day that I spent with so many talented and accomplished women at Project W's WEB program for Health Tech. It is a difficult road that we female founders have chosen, and I can't thank Lynn Loacker, Amanda McFadden, and the DWT team enough for providing this opportunity to learn from and be supported by women who have paved the way.

We're honored to be featured by the National Heart, Lung, and Blood Institute in this new article about our VitalO₂ device. NHLBI's non-dilutive funding for Opticyte has been essential for the product development and research on Cell O₂'s clinical value. A huge thank you to NHLBI for the support! https://lnkd.in/g4YihsDa

Exciting news: our CEO Lori Arakaki was selected as part of this year's Project W WEB cohort! It's an honor to be included alongside other innovative female founders building the #FutureOfHealthCare.

Thanks to Creative Destruction Lab for including Opticyte as part of its recent CDL-Vancouver Alumni Showcase. It was a fantastic event where Lori Arakaki pitched our company and demoed the VitalO₂ technology, engaging in meaningful conversations with investors and other entrepreneurs. We're thankful to be part of a community of such ambitious, passionate innovators. #CDL #AlumniShowcase #Innovation #Entrepreneurship #Tech #Investing

This week Lori Arakaki will be headed to DeviceTalks Boston as part of the MedTech Innovator All-Stars Alumni Investor Forum. We're excited for her to get to connect with investors and other innovators in the #MedTech space as she shares how our VitalO₂ device can transform identification and treatment of #sepsis and organ failure. If you'll be at the conference too, make sure to say hi! 👋 And check out the other MTI portfolio companies: https://lnkd.in/ebkiTACC #DTBoston2024 #FutureofHealthCare

We're thrilled that Opticyte was selected to be part of CDL-Vancouver's Alumni Showcase next month, where Lori Arakaki will be pitching alongside 29 other #MedTech companies.

Attending today’s FDA public meeting on pulse oximeters has been inspiring. Here at Opticyte we are encouraged by the attention from clinicians, professional societies, regulators, industry stakeholders, and patient representatives on improving pulse oximetry performance for people of all skin tones. The problem with accuracy in individuals with darker skin tones is more and more widely recognized and a concerted effort across the field is being made to address the issue. We are committed to ensuring that our VitalO₂ technology is developed to be accurate in all skin tones. It is clear there is a need and demand for such a device. https://lnkd.in/g-zNR9qV